Updated time: 2020-11-13 18:26:13
03A-1090710
2020-11-13
Patent pending
There are two approaches to produce anticoagulant low-molecular-weight heparin (LMWHP), either by degradation of naturally available heparin (HP) or pure organic synthesis. Extraction and isolation of LMWHP from naturally available fractioned heparin for having unique structure and size remains extremely challenge due to inherit heterogeneity in nature HP. On the other hand, carbohydrate organic synthesis of LMWHP requires many steps and the overall yield is extremely low. Here we propose a novel approach using vaccinia virus envelope protein A27, having high binding affinity to HP as a bait to fish out and purify anticoagulant LMWHP. By this means, one is able to purify LMWHP with high yield which has high commercial value in medical applications.
- Oligosaccharide heparin of specific molecular structure can be purified.
- Oligosaccharide heparins of certain size and molecular structure are selected.
- High purity oligosaccharide heparin can be stored in either aqueous solution or in lyophilized powdered form, ready for transportation and further modification if desired.
- Antithrombotic agents for cardiovascular diseases
- Anticoagulant medical treatment to prevent blood clots during hip replacement surgery
- Anticoagulant medical treatment to prevent blood clots during kidney dialysis

The rate performance of Y1 (black) and standard graphite (red) LIB electrodes.
Der-Lii M. Tzou、 Kathleen Joyce Dela Rosa Carillo
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Using vaccinia virus envelope protein A27 to fish out anticoagulant oligosaccharide heparin